Page 1

Арух MEDICAL Energy Elevating Lives EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 248 % year - over - year in Q2 CLEARWATER , FL - August 12 , 2021 - Apyx Medical Corporation ( NASDAQ : APYX ) ( the “ Company ” ) , a maker of medical devices and supplies and the developer of Helium Plasma Technology , marketed and sold as Renuvion® in the cosmetic surgery market and J - PlasmaⓇ in the hospital surgical market , today reported financial results for its second quarter ended June 30 , 2021 and updated its financial outlook for the full year ending December 31 , 2021 . Second Quarter 2021 Financial Summary : • • • Total revenue of $ 11.2 million , up 161 % year - over - year . о о Advanced Energy revenue of $ 10.0 million , up 248 % year - over - year . OEM revenue of $ 1.2 million , down 13 % year - over - year . Net loss attributable to stockholders of $ 4.0 million , compared to net loss of $ 4.7 million for the second quarter of 2020. Net loss in the second quarter of 2020 included an income tax benefit of $ 1.5 million . Adjusted EBITDA loss of $ 2.4 million , compared to adjusted EBITDA loss of $ 4.9 million for the second quarter of 2020 . As of June 30 , 2021 , the Company had cash and cash equivalents of $ 34.7 million , compared to $ 41.9 million as of December 31 , 2020. As of June 30 , 2021 , the Company had working capital of $ 50.8 million , including expected cash tax refunds of approximately $ 7.5 million the Company expects to receive during 2021 or 2022 related to the net operating loss carrybacks resulting from the 2020 CARES Act . Second Quarter 2021 Operating Highlights : • On June 1 , 2021 , the Company announced that it had submitted a 510 ( k ) premarket notification to the U.S. Food and Drug Administration ( “ FDA ” ) , which is intended to obtain a specific clinical indication for the use of Renuvion® in dermal resurfacing procedures . Management Comments : " We are pleased to deliver exceptional growth in sales of our Advanced Energy products which exceeded our expectations for the second quarter , reflecting solid execution by our team and continued improvement in the broader operating environment , ” said Charlie Goodwin , President and Chief Executive Officer . “ Most notably , we saw impressive growth in global sales of our Advanced Energy handpieces , which increased by over 270 % year - over - year , driven by utilization - based demand both domestically and internationally . We were also pleased to see important contributions from global sales of our generators , which increased by more than 210 % year - over - year , reflecting strong adoption of our technology in the U.S. and key international markets as the capital equipment environment continued to recover . " Mr. Goodwin continued : " We are increasing our 2021 revenue outlook today to reflect both our stronger - than - expected sales performance during the second quarter , as well as our improved expectations for the second half of the year . While the pace and timing of recovery in the global capital equipment environment remains uncertain , we expect to see continued improvement coupled with strong utilization trends as we move through the balance of the year . We look forward to building on our recent momentum by continuing to raise awareness of our innovative Helium Plasma Technology and its potential benefits for surgeons and patients around the world . "